An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Navidea Biopharmaceuticals
Navidea Biopharmaceuticals
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
AIDS Malignancy Consortium
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service
NIH AIDS Clinical Trials Information Service